文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

肿瘤芽生作为pT1期结直肠癌淋巴结转移和局部复发的危险因素:一项系统评价和荟萃分析

Tumor Budding as a Risk Factor for Lymph Node Metastasis and Local Recurrence in pT1 Colorectal Cancer: A Systematic Review and Meta-Analysis.

作者信息

Zhang Heng, Simmer Femke, Lugli Alessandro, Nagtegaal Iris D

机构信息

Department of Pathology, Radboud University Medical Center, Nijmegen, Gelderland, The Netherlands.

Institute for Tissue Medicine and Pathology, University of Bern, Bern, Switzerland.

出版信息

Gastro Hep Adv. 2025 May 27;4(9):100713. doi: 10.1016/j.gastha.2025.100713. eCollection 2025.


DOI:10.1016/j.gastha.2025.100713
PMID:40761702
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12320163/
Abstract

BACKGROUND AND AIMS: Implementation of population screening programs resulted in an increase in early colorectal cancer (CRC, pT1). For these small CRC, endoscopic local resection is the preferred treatment. However, the presence of lymph node metastasis (LNM) and risk of local recurrence might require additional surgery. Tumor budding (TB) is a well-known biomarker for adverse outcomes in pT1 CRC. This study aims to further explore the relationship between TB and in pT1 CRC and to clarify the relationship between TB and local recurrence, to provide more strategies for the selection of surgical treatment. METHODS: A systematic review was conducted using the MEDLINE and EMBASE databases to investigate the relationship between TB and LNM and local recurrence in pT1 CRC. Meta-analysis based on a random-effects model was performed to evaluate the relationship between TB and these 2 factors. RESULTS: A total of 57 observational studies were included in the meta-analysis, with a total of 24,956 patients. High-grade TB was significantly associated with both LNM (risk ratio (RR) = 4.04, 95% confidence interval (CI), 3.52-4.64, I = 56.11%, < .001) and local recurrence (RR = 2.35, 95% CI, 1.21-4.54, I = 26.18%, = .01). Sensitivity analysis confirmed the robustness of our pooled results. Subgroup analysis also explored possible sources of heterogeneity. For LNM, geographical location (Asia: RR = 4.22, 95% CI, 3.64-4.89; Others: RR = 2.72, 95% CI, 2.08-3.57, = .01) and year of publication (<2015: RR = 4.96, 95% CI, 4.01-6.15; ≥2015: RR = 3.58, 95% CI, 2.99-4.29, = .02) showed significant differences in the subgroup analysis. We cannot rule out publication bias for LNM risk. CONCLUSION: Our findings confirm that TB is a strong predictor of local recurrence, but in particular of LNM in pT1 CRC and offers effective guidance for selecting further surgical treatment strategies.

摘要

背景与目的:人群筛查项目的实施导致早期结直肠癌(CRC,pT1)的检出率增加。对于这些小的结直肠癌,内镜下局部切除是首选治疗方法。然而,存在淋巴结转移(LNM)和局部复发风险可能需要额外的手术。肿瘤芽生(TB)是pT1结直肠癌不良预后的一个众所周知的生物标志物。本研究旨在进一步探讨TB与pT1结直肠癌之间的关系,并阐明TB与局部复发之间的关系,为手术治疗的选择提供更多策略。 方法:使用MEDLINE和EMBASE数据库进行系统评价,以研究TB与pT1结直肠癌中LNM和局部复发之间的关系。基于随机效应模型进行荟萃分析,以评估TB与这两个因素之间的关系。 结果:荟萃分析共纳入57项观察性研究,共24956例患者。高级别TB与LNM(风险比(RR)=4.04,95%置信区间(CI),3.52 - 4.64,I² = 56.11%,P <.001)和局部复发(RR = 2.35,95%CI,1.21 - 4.54,I² = 26.18%,P = 0.01)均显著相关。敏感性分析证实了我们汇总结果的稳健性。亚组分析还探讨了异质性的可能来源。对于LNM,地理位置(亚洲:RR = 4.22,95%CI,3.64 - 4.89;其他地区:RR = 2.72,95%CI,2.08 - 3.57,P = 0.01)和发表年份(<2015年:RR = 4.96,95%CI,4.01 - 6.15;≥2015年:RR = 3.58,95%CI,2.99 - 4.29,P = 0.02)在亚组分析中显示出显著差异。我们不能排除LNM风险的发表偏倚。 结论:我们的研究结果证实,TB是局部复发的有力预测指标,尤其是pT1结直肠癌中LNM的有力预测指标,并为选择进一步的手术治疗策略提供了有效的指导。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ad/12320163/4df15129297d/figs5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ad/12320163/f4d01d4a4682/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ad/12320163/bdd32f19a3aa/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ad/12320163/77763a026251/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ad/12320163/68505d03ee30/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ad/12320163/073c0333d4e1/figs1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ad/12320163/d472c07ec91c/figs2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ad/12320163/28755afaf8eb/figs3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ad/12320163/4339edbcd079/figs4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ad/12320163/4df15129297d/figs5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ad/12320163/f4d01d4a4682/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ad/12320163/bdd32f19a3aa/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ad/12320163/77763a026251/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ad/12320163/68505d03ee30/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ad/12320163/073c0333d4e1/figs1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ad/12320163/d472c07ec91c/figs2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ad/12320163/28755afaf8eb/figs3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ad/12320163/4339edbcd079/figs4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ad/12320163/4df15129297d/figs5.jpg

相似文献

[1]
Tumor Budding as a Risk Factor for Lymph Node Metastasis and Local Recurrence in pT1 Colorectal Cancer: A Systematic Review and Meta-Analysis.

Gastro Hep Adv. 2025-5-27

[2]
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Cochrane Database Syst Rev. 2017-12-22

[3]
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Cochrane Database Syst Rev. 2020-1-9

[4]
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Cochrane Database Syst Rev. 2021-4-19

[5]
Selenium for preventing cancer.

Cochrane Database Syst Rev. 2018-1-29

[6]
Electronic cigarettes for smoking cessation.

Cochrane Database Syst Rev. 2022-11-17

[7]
Electronic cigarettes for smoking cessation.

Cochrane Database Syst Rev. 2025-1-29

[8]
Electronic cigarettes for smoking cessation.

Cochrane Database Syst Rev. 2021-9-14

[9]
Systemic treatments for metastatic cutaneous melanoma.

Cochrane Database Syst Rev. 2018-2-6

[10]
Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma.

Cochrane Database Syst Rev. 2015-5-16

本文引用的文献

[1]
Dilemmas in the Clinical Management of pT1 Colorectal Cancer.

Cancers (Basel). 2023-7-6

[2]
Lymph node metastasis in T1 colorectal cancer: Risk factors and prediction model.

Oncol Lett. 2023-3-28

[3]
Nomogram as a novel predictive tool for lymph node metastasis in T1 colorectal cancer treated with endoscopic resection: a nationwide, multicenter study.

Gastrointest Endosc. 2023-6

[4]
[Endoscopic treatment of early colorectal cancer].

Vnitr Lek. 2022

[5]
Prognostic Factors for Lymph Node Metastases in pT1 Colorectal Cancer Differ According to Tumor Morphology: A Nationwide Cohort Study.

Ann Surg. 2023-1-1

[6]
Risk Factors for Predicting Lymph Node Metastasis in Submucosal Colorectal Cancer.

J Anus Rectum Colon. 2022-7-28

[7]
Composite scoring system and optimal tumor budding cut-off number for estimating lymph node metastasis in submucosal colorectal cancer.

BMC Cancer. 2022-8-6

[8]
Subpopulation analysis of survival in high-risk T1 colorectal cancer: surgery versus endoscopic resection only.

Gastrointest Endosc. 2022-12

[9]
Tumor Budding as a Predictive Marker of Relapse and Survival in Patients With Stage II Colon Cancer.

In Vivo. 2022

[10]
The Importance of Being "That" Colorectal pT1: A Combined Clinico-Pathological Predictive Score to Improve Nodal Risk Stratification.

Front Med (Lausanne). 2022-2-14

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索